AU Patent

AU2023202903A1 — Pharmaceutical compositions and uses directed to lysosomal storage disorders

Assigned to Intrabio Ltd · Expires 2023-05-25 · 3y expired

What this patent protects

The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administrering acetyl-leucine or a pharamaceutically acceptable salt thereof.

USPTO Abstract

The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administrering acetyl-leucine or a pharamaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023202903A1
Jurisdiction
AU
Classification
—
Expires
2023-05-25
Drug substance claim
No
Drug product claim
No
Assignee
Intrabio Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.